Aiforia estimates that the transition to IFRS reporting will improve the comparability of financial figures and increase the interest of international investors in the company. The IFRS transition date was 1 January 2022.

Aiforia will publish its first IFRS financial statements for the financial period ending 31. December 2023.

Further inquiries

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc

tel. +358405009878

https://investors.aiforia.com/ 

Certified Adviser

UB Securities Ltd

ubs@unitedbankers.fi  

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com